Fundraising Fox
Arrivent
Newtown Square, US · Founded 2021 · 86 employees on LinkedIn · 11 known investors
Find your way into Arrivent
1,101 people in our graph can introduce you to the Arrivent team.
Sign up to see every warm intro you have to Arrivent
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Arrivent team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers. Its pipeline centers on its lead candidate firmonertinib (formerly furmonertinib) and novel oncology therapeutics such as next-generation antibody drug conjugates.
Founders & leadership
Arrivent was founded in 2021 by Zhengbin (Bing) Yao.
Board
Investors · 11
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
.png)
How we know: General Catalyst's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · Not right? Tell us
How we know: HongShan Capital Group's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: OrbiMed's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$260M disclosed across 2 rounds · 2021–2022
▶$110MraisedDec 2022 · 17 investors · BiotechnologyRule 506(b)
- Stuart LutzkerDirector
- James HealyDirector
- Carl GordonDirector
- Jason ZhangDirector
- Zhengbin (Bing) YaoExecutive Officer, Director
- Bahija JallalDirector
- Cong XuDirector
- Offering amount
- $145M
- Amount sold
- $110M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$150MraisedFeb 2022 · 10 investors · BiotechnologyRule 506(b)
- Jason ZhangDirector
- Cong XuDirector
- Zhengbin (Bing) YaoExecutive Officer, Director
- Stuart LutzkerDirector
- Offering amount
- $150M
- Amount sold
- $150M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Arrivent do?
- ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers. Its pipeline centers on its lead candidate firmonertinib (formerly furmonertinib) and novel oncology therapeutics such as next-generation antibody drug conjugates.
- Who founded Arrivent?
- Arrivent was founded by Zhengbin (Bing) Yao in 2021.
- Who are Arrivent's investors?
- Arrivent's investors include Catalio Capital Management, LP, Foresite Capital, General Catalyst, HBM Healthcare Investments, HBM Partners, HongShan Capital Group, LAV, Lilly Asia Ventures and 3 more.
- How much funding has Arrivent raised?
- Arrivent has disclosed $260M raised across 2 rounds.
- Where is Arrivent headquartered?
- Arrivent is headquartered in Newtown Square, US.